Kobayashi Pharmaceutical 結果共4筆

Explore the ongoing controversy in Taiwan over Kobayashi Pharmaceutical’s red yeast product, as the FDA investigates 58 cases of adverse reactions without confirmed causality, amidst reports of kidney disease and deaths in Japan. Taiwan responds with preventive recalls and consumer protection measures.

Taipei (TVBS News) reports that Taiwan’s Food and Drug Administration (FDA) has taken action after businesses reported using red yeast rice raw materials from Japan’s Kobayashi Pharmaceutical, linked to kidney disease. Preventive measures have been taken, with products removed from shelves. FDA Director-General Wu Hsiu-mei oversees the situation to safeguard consumer safety.

Kobayashi Pharmaceutical’s red yeast rice health food products have been linked to four deaths in Japan, with over 100 hospitalizations reported. Taiwan’s FDA is urging businesses to report affected products to ensure food safety.

Taiwan’s Minister of Health and Welfare Hsueh Jui-yuan announces the removal of products made with red yeast rice from Japan due to adverse reactions. Kobayashi Pharmaceutical’s recall follows reports of acute kidney failure, with one reported death under investigation.